Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis

被引:0
作者
Hebert Alberto Vargas
Rachel Schor-Bardach
Niamh Long
Anna N. Kirzner
Jane D. Cunningham
Debra A. Goldman
Chaya S. Moskowitz
Ramon E. Sosa
Evis Sala
David M. Panicek
Hedvig Hricak
机构
[1] Memorial Sloan Kettering Cancer Center,Department of Radiology
[2] Memorial Sloan Kettering Cancer Center,Department of Epidemiology and Biostatistics
来源
Abdominal Radiology | 2017年 / 42卷
关键词
MRI; Prostate cancer; Bone metastases; Staging; Imaging; Detection;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:271 / 277
页数:6
相关论文
共 68 条
[1]  
DeSantis CE(2014)Cancer treatment and survivorship statistics, 2014 CA Cancer J Clin. 64 252-271
[2]  
Lin CC(2014)EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol. 65 124-137
[3]  
Mariotto AB(2012)Radical prostatectomy versus observation for localized prostate cancer N Engl J Med. 367 203-213
[4]  
Heidenreich A(2014)Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer Eur Radiol. 24 3161-3170
[5]  
Bastian PJ(2015)The role of MRI in active surveillance for prostate cancer Curr Urol Rep. 16 507-92
[6]  
Bellmunt J(2013)ACR appropriateness criteria prostate cancer–pretreatment detection, staging, and surveillance J Am Coll Radiol. 10 83-139
[7]  
Wilt TJ(2004)Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension Radiology. 232 133-3711
[8]  
Brawer MK(2014)Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score Clin Cancer Res. 20 3705-S24
[9]  
Jones KM(2008)Evaluating localized prostate cancer and identifying candidates for focal therapy Urology. 72 S12-1738
[10]  
Gondo T(2012)Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer J Urol. 188 1732-977